Discover phases of acute ischemic stroke care, from rapid recognition to long-term recovery strategies that neurologists use ...

Health system pharmacists and physicians are monitoring a wave of expected new drug approvals between late 2024 and third quarter of 2025. A recent article published in the American Journal of ...

Bioxodes announces positive Phase 2a interim data for BIOX-101 in intracerebral hemorrhagic stroke patientsPrimary endpoint met, no drug-related serious adverse events Positive hematoma and edema ...

Sanofi is handing back a phase 2-stage natural killer (NK) cell engager and canceling another cancer trial as the Big Pharma ...

Gosselies, Belgium Saturday, April 26, 2025, 16:00 Hrs [IST] ...

an injectable Factor XI/XIa-targeting antibody that generated encouraging results in a phase 2b trial earlier this year. Milvexian is in three late-stage studies in AF, stroke, and acute coronary ...

The molecular mechanism behind why heart attacks can vary in severity depending on the time of day has been uncovered, potentially paving the way for innovative treatments that align with the natural ...

The molecular mechanism behind why heart attacks can vary in severity depending on the time of day has been uncovered by ...

Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian ... studies in ischaemic stroke (PACIFIC-STROKE) and acute myocardial infarction (PACIFIC-AMI) reported ...

Limited’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has surged by 7.99%, which has investors questioning if this is right ...